ChuanLiang Cui # , Xuan Wang # , Bin Lian , Qing Ji , Li Zhou, Zhihong Chi, Lu Si , Xinan Sheng , Yan Kong , Jiayi Yu, Siming Li , Lili Mao , Bixia Tang , Jie Dai , Xieqiao Yan, Xue Bai , Robert Andtbacka , Jun Guo # OrienX010, an oncolytic virus, in patients with unresectable stage IIIC–IV melanoma: a phase Ib study,Journal for ImmunoTherapy of Cancer,2022, 10(4): e004307

Xuan Wang # , Hongming Pan , Jiuwei Cui , Xiao Chen , Won-Hee Yoon , Matteo S Carlino , Xin Li , Hui Li , Juan Zhang, Jingchao Sun , Jun Guo , Chuanliang Cui * SAFFRON-103: a phase Ib study of sitravatinib plus tislelizumab in anti-PD-(L)1 refractory/resistant advanced melanoma,Immunotherapy,16(4): 243-256

Xuan Wang #, Xiaowen Wu #, Yue Yang , Weiran Xu, Hui Tian , Bin Lian, Zhihong Chi , Lu Si , Xinan Sheng , Yan Kong , Li Zhou , Lili Mao , Siming Li , Bixia Tang , Xieqiao Yan , Xue Bai , Jun Guo , ChuanLiang Cui * Apatinib combined with camrelizumab in advanced acral melanoma patients: An open-label, single-arm phase 2 trial,European Journal of Cancer,2023, 182: 57-65

Xuan Wang # , Zhiguo Luo # , Jing Chen # , Yu Chen , Dongmei Ji , Li Fan , Ling Chen , Qian Zhao , Pei Hu , Peng Sun , Zhongwei Jia , Jun Guo *, Lu Si* First-in-human phase I dose-escalation and doseexpansion trial of the selective MEK inhibitor HL-085 in patients with advanced melanoma harboring NRAS mutations,BMC Medicine,2022, 21(1)

Li Zhou # , Xuan Wang #, Zhihong Chi , Xinan Sheng , Yan Kong , Lili Mao , Bin Lian , Bixia Tang, Xieqiao Yan , Xue Bai , Siming Li , Jun Guo , Chuanliang Cui * , Lu Si * Association of NRAS Mutation With Clinical Outcomes of Anti-PD-1 Monotherapy in Advanced Melanoma: A Pooled Analysis of Four Asian Clinical Trials,FRONTIERS IN IMMUNOLOGY,2021. 12(691032)

Xuan Wang #, Weiran Xu# , Zhihong Chi , Lu Si , Xinan Sheng , Yan Kong , Li Zhou , Lili Mao, Bin Lian, Bixia Tang , Xieqiao Yan , Xue Bai , Chuanliang Cui * , Jun Guo * Chemotherapy combined with antiangiogenic drugs as salvage therapy in advanced melanoma patients progressing on PD-1 immunotherapy,Transl Oncol,2021 Jan;14(1):100949

Xuan Wang #, Qing Ji # , Xieqiao Yan , Bin Lian , Lu Si , Zhihong Chi , Xinan Sheng , Yan Kong , Lili Mao , Xue Bai , Bixia Tang , Siming Li , Li Zhou , Chuanliang Cui * , Jun Guo *The Impact of Liver Metastasis on Anti-PD-1 Monoclonal Antibody Monotherapy in Advanced Melanoma Analysis of Five Clinical Studies,Frontiers in Oncology,2020, 10(546604)

溶瘤病毒联合 PD-1 抑制剂治疗黑色素瘤机制及疗效预测因子研究, 课题负责人, 2024.1.1～2026.12.31, 北京市医管中心；北京市属医院科研培育计划

SOX17基因在免疫联合抗血管生成治疗晚期黑色素瘤中的作用和机制研究, 课题负责人, 2022.11.1～2024.9.30, CSCO；希思科—恒瑞肿瘤研究基金项目

色素瘤中糖酵解代谢酶对T细胞耗竭的调节及其对PD-1单抗治疗的影响和机制研究, 课题负责人, 2022.4.1～2023.12.31, 北京大学临床医学校内课题

MEN1在NRAS突变的黑色素瘤对MEK抑制剂耐药中的作用及其机制, 课题负责人, 2021.1.1～2021.12.31, 北京大学青年培育

中国BRAF突变的进展期黑色素瘤靶向-免疫治疗转化中生物标记物的探索, 课题负责人, 2020.1.1～2021.12.31, 北京大学肿瘤医院院内基金